Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.11Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong operational and financial momentum: substantial revenue growth (Q4 +83% YoY), material margin improvement (adjusted EBITDA margin up to 29%), multiple successful launches (Desmota, Galzin relaunch) and an accretive cash acquisition (Hemangiol). Management provided ambitious but concrete 2026 guidance (> $110M revenue, ≥30% adjusted EBITDA margin) and laid out multi-year targets that tie commercial execution to margin expansion. Near-term headwinds include Q4 cash outflow driven by large Medicaid rebates and newly triggered FDA program fees, some margin volatility from ex-U.S. Incralex orders, and execution/timing risks around label expansions and clinical studies. Overall, the positives—rapid revenue scaling, improving profitability, multiple product launch catalysts, and a strengthened pipeline—appear to significantly outweigh the manageable near-term financial and execution risks.Company Guidance
Strong Revenue Growth
Q4 product revenue of $21.3M, up 83% year-over-year (Q4 2024: $11.6M); company more than doubled revenue in 2025 versus 2024 and provided 2026 guidance of revenue expected to exceed $110M.
Improving Profitability and Margins
Adjusted EBITDA margin improved to 29% in 2025 from 18% in the prior-year period; GAAP net income of $1.5M in Q4 and non-GAAP net income of $5.4M for 2025. Adjusted gross profit was $15.5M (73%) in 2025 versus $6.8M (59%) in prior year; company expects adjusted EBITDA margin of at least 30% in 2026 and adjusted gross margin comfortably above 70% (ramping to 75%–80%).
Desmota FDA Approval and Early Commercial Traction
Desmota (oral liquid desmopressin) FDA-approved in Feb 2026 and launched within two weeks; offers unique liquid formulation with clean label (no age restriction) addressing pediatric and adult central diabetes insipidus. Management estimates average net revenue of ~ $80,000 per patient per year and maintains $30M–$50M potential peak sales guidance; multiple patents extend to 2044.
Successful Product Relaunches and Patient Growth (Incrolex / Incralex)
Incrolex patient count increased from 67 at acquisition (Dec 2024) to over 100 on therapy with a goal of 120 by year end; company pursuing label harmonization study (open-label ~30 patients, first patient expected in Q3) which could increase the U.S. market opportunity up to fivefold if successful.
Alkindi & Kindivy Momentum
Alkindi and Kindivy franchise showing strong growth; Alkindi had its strongest year in 2025 in patient count and referrals. Management estimates target pediatric market ~5,000 children under age eight, has captured ~12% to date, and believes ~20% market share would support at least $50M peak annual sales.
Hemangiol Acquisition and Rare-Disease Commercial Strategy
Acquired Hemangiol for $14M in cash, relaunch planned May 1 with seven experienced commercial hires; Hemangiol treats an estimated 5,000–10,000 infants annually and management expects to optimize distribution, reduce gross-to-net, introduce zero copay, and position Hemangiol as a major product by 2027.
Galzin (Galcen) Growth and ET700 Opportunity
Galzin reached ~300 active patients one year after relaunch with a sizable addressable population still using OTC zinc; ET700 extended-release program to begin PET proof-of-concept in April with topline later in the year and management projecting ET700 peak potential in excess of $100M if successful.
Robust Pipeline and Ambitious Long-Term Targets
Busy clinical year planned (Candivy, Incrolex label harmonization, ET700, PK studies for AMGLIDIA and ET800). NDA plans include AMGLIDIA by year-end and ET800 in 2027. Company announced new long-term goals: build largest U.S. rare disease portfolio (13–14 products), exit 2027 at $200M revenue run rate, 50% adjusted EBITDA margin by 2028, and $500M revenue by 2030.
ETON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ETON Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $20.77 | $22.32 | +7.46% |
Nov 06, 2025 | $19.14 | $16.90 | -11.70% |
Aug 07, 2025 | $15.26 | $17.14 | +12.32% |
May 13, 2025 | $17.07 | $17.12 | +0.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eton Pharmaceuticals Inc (ETON) report earnings?
Eton Pharmaceuticals Inc (ETON) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Eton Pharmaceuticals Inc (ETON) earnings time?
Eton Pharmaceuticals Inc (ETON) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ETON EPS forecast?
ETON EPS forecast for the fiscal quarter 2026 (Q1) is 0.11.
